ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,587.00
0.23%
S&P ASX All Technology
2,972.40
0.12%
Brent Oil
83.435
-0.13%
US Dollar vs AUD
1.53377
0.18%
Bitcoin
58,784.91
0.95%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Entera Bio Ltd (ENTX)

  7. Entera Bio Ltd (ENTX) News

ENTX Entera Bio Ltd

1.97
-0.03 (-1.50%)
Last Updated: 00:13:01
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Entera Bio Ltd ENTX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-0.03 -1.50% 1.97 00:13:01
Open Price Low Price High Price Close Price Previous Close
2.05 1.96 2.05 2.00
more quote information »

Recent News

Date Time Source Heading
08/4/202422:30GLOBEEntera Bio Announces Publication of Oral PTH(1-34) Peptide..
26/3/202423:30GLOBEEntera Bio Announces Key Regulatory Milestone for Oral..
20/3/202423:00GLOBEEntera Bio Announces Robust Pharmacokinetic Data for..
09/3/202408:25EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/3/202408:12EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
09/3/202408:10EDGAR2Form 8-K - Current report
09/3/202408:05GLOBEEntera Bio Announces Full Year 2023 Financial Results and..
05/3/202400:30EDGAR2Form 8-K - Current report
05/3/202400:30GLOBEEntera Bio Regains Compliance with Nasdaq Minimum Bid Price..
16/2/202409:10EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/2/202416:15EDGAR2Form EFFECT - Notice of Effectiveness
14/2/202422:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
03/2/202408:19EDGAR2Form 8-K - Current report
03/2/202408:17EDGAR2Form S-3 - Registration statement under Securities Act of..
31/1/202400:30GLOBEEntera Bio to Present at the Oppenheimer 34th Annual..
17/1/202400:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202410:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202410:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202408:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202408:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202408:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202400:00EDGAR2Form 8-K - Current report
28/12/202300:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202300:00EDGAR2Form 8-K - Current report
27/12/202300:00GLOBEEntera Bio Announces Closing of Private Placement - Extends..
30/11/202300:30GLOBEInterim Results from Ongoing Clinical Study Confirm EB613..
14/11/202323:30GLOBEEntera Bio Reports Q3 2023 Financial Results, Highlights..
10/11/202306:30GLOBEEntera Bio Reports Key Milestone Relating to Oral PTH (1-34)..
16/10/202323:00GLOBEEntera Bio Reports Rapid Pharmacodynamic (PD) Response and..
15/9/202307:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/9/202307:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/9/202306:05EDGAR2Form 8-K - Current report
12/9/202322:30GLOBEEntera Bio Announces Collaboration with OPKO Biologics to..
05/9/202322:00GLOBEEntera Bio to Participate in Upcoming Investor Conferences
24/8/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/8/202322:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
22/8/202323:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202322:30GLOBEEntera Bio to Present Two Abstracts on its First-in-Class,..
16/8/202306:10EDGAR2Form DEF 14A - Other definitive proxy statements
12/8/202306:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/8/202306:16EDGAR2Form 8-K - Current report
12/8/202306:05GLOBEEntera Bio Announces Q2 2023 Financial Results and Corporate..
01/7/202306:06EDGAR2Form 8-K - Current report
07/6/202321:30GLOBEEntera Bio Adds Sanofi Commercial Leader, Haya Taitel to its..
06/5/202306:05GLOBEEntera Bio Announces Q1 2023 Financial Results and Corporate..
03/5/202323:34GLOBEEntera’s Oral Delivery of GLP-2 Pre-Clinical Data to be..

Your Recent History

NASDAQ
ENTX
Entera Bio
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved